31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient
blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and
pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Parkinson's Disease (PD)
within three (3) years of Screening. The primary endpoint is the ratio of the oxidized to
reduced form of nicotinamide adenine dinucleotide (NAD+:NADH) measured non-invasively by
31phosphorous magnetic resonance spectroscopy (31P-MRS).